GC 1126A
Alternative Names: GC-1126ALatest Information Update: 06 Oct 2023
Price :
$50 *
At a glance
- Originator GC Pharma
- Developer GC Biopharma
- Class Recombinant proteins
- Mechanism of Action ADAMTS protein modulators; Autoantibody inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Thrombotic thrombocytopenic purpura
Highest Development Phases
- Preclinical Thrombotic thrombocytopenic purpura